Of 9 guidance figures from Moderna's earnings releases that Stock Atlas has scored against the reported result, 2 came in above the guide, 3 in range and 4 below. It met or beat its own guidance 56% of the time.
| Period | Measure | Guided | Reported | Result |
|---|---|---|---|---|
| FY2025 | Capital Expenditures | $300.00M | $192.00M | below |
| FY2025 | Revenue | $1.60B to $2.00B | $1.94B | in range |
| FY2024 | Capital Expenditures | $1.20B | $1.05B | below |
| FY2024 | Revenue | $3.00B to $3.50B | $3.24B | in range |
| FY2023 | Revenue | $6.00B | $6.85B | above |
| FY2023 | Capital Expenditures | $1.00B | $707.00M | below |
| FY2022 | Revenue | $17.00B to $22.00B | $19.26B | in range |
| FY2021 | Revenue | $15.00B to $18.00B | $18.47B | above |
Above means the reported figure beat the top of the range, in range that it landed inside it or on a point guide, below that it missed. Every guide and revision, and screens across companies, are in the research platform.
Do companies beat their own guidance? The study · Back to Moderna financials
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Moderna (MRNA) guidance record”, stockatlas.com/companies/MRNA/guidance/, data as of 3 November 2026. Links to this page are welcome.
